Evidence map›Paper›PMID 37750750›Full record

ArticleMicrobial genomics2023

Borderline

Pauline Lempens, Armand Van Deun, Kya J M Aung, Mohammad A Hossain, Mahboobeh Behruznia, Tom Decroo, Leen Rigouts, Bouke C de Jong, Conor J Meehan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbial genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Extensive Endemic Transmission of Multidrug-ResistantOpen forum infectious diseases · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pauline LempensUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Armand Van DeunIndependent Consultant, Leuven, Belgium.
Kya J M AungDamien Foundation Bangladesh, Dhaka, Bangladesh.
Mohammad A HossainDamien Foundation Bangladesh, Dhaka, Bangladesh.
Mahboobeh BehruzniaDepartment of Biosciences, Nottingham Trent University, Nottingham, UK.
Tom DecrooUnit of HIV and TB, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Leen RigoutsUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Bouke C de JongUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Conor J MeehanUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Funding

British Heart FoundationWellcome Trust
6 · The paper itself

Abstract

The spread of multidrug-resistant tuberculosis (MDR-TB) is a growing problem in many countries worldwide. Resistance to one of the primary first-line drugs, rifampicin, is caused by mutations in the

Indexed as

Bacterial ProteinsMycobacterium tuberculosisTuberculosis, Multidrug-ResistantBangladeshDNA-Directed RNA PolymerasesHumansMutationRifampinBacterial ProteinsDNA-Directed RNA PolymerasesRifampinrpoB protein, Mycobacterium tuberculosisDrug resistanceMycobacteriumTransmissiontuberculosis

Identifiers

PMID37750750
PMCPMC10569737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.